1
|
Gomes DC, Medeiros TS, Alves Pereira EL, da Silva JFO, de Freitas Oliveira JW, Fernandes-Pedrosa MDF, de Sousa da Silva M, da Silva-Júnior AA. From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease. Int J Mol Sci 2023; 24:13778. [PMID: 37762080 PMCID: PMC10530915 DOI: 10.3390/ijms241813778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 07/31/2023] [Accepted: 08/05/2023] [Indexed: 09/29/2023] Open
Abstract
Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi. Benznidazole and nifurtimox are the two approved drugs for their treatment, but both drugs present side effects and efficacy problems, especially in the chronic phase of this disease. Therefore, new molecules have been tested with promising results aiming for strategic targeting action against T. cruzi. Several studies involve in vitro screening, but a considerable number of in vivo studies describe drug bioavailability increment, drug stability, toxicity assessment, and mainly the efficacy of new drugs and formulations. In this context, new drug delivery systems, such as nanotechnology systems, have been developed for these purposes. Some nanocarriers are able to interact with the immune system of the vertebrate host, modulating the immune response to the elimination of pathogenic microorganisms. In this overview of nanotechnology-based delivery strategies for established and new antichagasic agents, different strategies, and limitations of a wide class of nanocarriers are explored, as new perspectives in the treatment and monitoring of Chagas disease.
Collapse
Affiliation(s)
- Daniele Cavalcante Gomes
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (D.C.G.); (T.S.M.); (E.L.A.P.); (J.F.O.d.S.); (M.d.F.F.-P.)
| | - Thayse Silva Medeiros
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (D.C.G.); (T.S.M.); (E.L.A.P.); (J.F.O.d.S.); (M.d.F.F.-P.)
| | - Eron Lincoln Alves Pereira
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (D.C.G.); (T.S.M.); (E.L.A.P.); (J.F.O.d.S.); (M.d.F.F.-P.)
| | - João Felipe Oliveira da Silva
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (D.C.G.); (T.S.M.); (E.L.A.P.); (J.F.O.d.S.); (M.d.F.F.-P.)
| | - Johny W. de Freitas Oliveira
- Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Centre of Health Sciences, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (J.W.d.F.O.); (M.d.S.d.S.)
| | - Matheus de Freitas Fernandes-Pedrosa
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (D.C.G.); (T.S.M.); (E.L.A.P.); (J.F.O.d.S.); (M.d.F.F.-P.)
| | - Marcelo de Sousa da Silva
- Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Centre of Health Sciences, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (J.W.d.F.O.); (M.d.S.d.S.)
| | - Arnóbio Antônio da Silva-Júnior
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil; (D.C.G.); (T.S.M.); (E.L.A.P.); (J.F.O.d.S.); (M.d.F.F.-P.)
| |
Collapse
|
2
|
Ntsekhe M. Pericardial Disease in the Developing World. Can J Cardiol 2023; 39:1059-1066. [PMID: 37201721 DOI: 10.1016/j.cjca.2023.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 05/10/2023] [Accepted: 05/10/2023] [Indexed: 05/20/2023] Open
Abstract
Pericardial disease in the developing world is dominated primarily by effusive and constrictive syndromes and contributes to the acute and chronic heart failure burden in many regions. The confluence of geography (location in the tropics), a significant burden of diseases of poverty and neglect, and a significant contribution of communicable diseases to the general burden of disease is reflected in the wide etiological spectrum of causes of pericardial disease. The prevalence of Mycobacterium tuberculosis in particular, is high throughout much of the developing world where it is the most frequent and important cause of pericarditis and is associated with significant morbidity and mortality. Acute viral/idiopathic pericarditis, which is the primary manifestation of pericardial disease in the developed world is believed to occur significantly less frequently in the developing world. Although diagnostic approaches and criteria to establish the diagnosis of pericardial disease are similar throughout the globe, resource constraints such as access to multimodality imaging and hemodynamic assessment are a major limitation in much of the developing world. These important considerations significantly influence the diagnostic and treatment approaches, and outcomes related to pericardial disease.
Collapse
Affiliation(s)
- Mpiko Ntsekhe
- The Division of Cardiology, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.
| |
Collapse
|
3
|
Brociek E, Tymińska A, Giordani AS, Caforio ALP, Wojnicz R, Grabowski M, Ozierański K. Myocarditis: Etiology, Pathogenesis, and Their Implications in Clinical Practice. BIOLOGY 2023; 12:874. [PMID: 37372158 PMCID: PMC10295542 DOI: 10.3390/biology12060874] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 05/29/2023] [Accepted: 06/14/2023] [Indexed: 06/29/2023]
Abstract
Myocarditis is an inflammatory disease of the myocardium caused by infectious or non-infectious agents. It can lead to serious short-term and long-term sequalae, such as sudden cardiac death or dilated cardiomyopathy. Due to its heterogenous clinical presentation and disease course, challenging diagnosis and limited evidence for prognostic stratification, myocarditis poses a great challenge to clinicians. As it stands, the pathogenesis and etiology of myocarditis is only partially understood. Moreover, the impact of certain clinical features on risk assessment, patient outcomes and treatment options is not entirely clear. Such data, however, are essential in order to personalize patient care and implement novel therapeutic strategies. In this review, we discuss the possible etiologies of myocarditis, outline the key processes governing its pathogenesis and summarize best available evidence regarding patient outcomes and state-of-the-art therapeutic approaches.
Collapse
Affiliation(s)
- Emil Brociek
- First Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland; (E.B.); (M.G.); (K.O.)
| | - Agata Tymińska
- First Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland; (E.B.); (M.G.); (K.O.)
| | - Andrea Silvio Giordani
- Cardiology, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35-100 Padova, Italy; (A.S.G.); (A.L.P.C.)
| | - Alida Linda Patrizia Caforio
- Cardiology, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35-100 Padova, Italy; (A.S.G.); (A.L.P.C.)
| | - Romuald Wojnicz
- Department of Histology and Cell Pathology in Zabrze, School of Medicine with the Division of Dentistry, Medical University of Silesia, 40-055 Katowice, Poland;
| | - Marcin Grabowski
- First Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland; (E.B.); (M.G.); (K.O.)
| | - Krzysztof Ozierański
- First Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland; (E.B.); (M.G.); (K.O.)
| |
Collapse
|
4
|
Abstract
The burden of cardiovascular diseases is sharply rising in low- and middle-income countries (LMICs). Along with the increasing rates of cardiovascular risk factors in these regions, there is a growing recognition of the contribution of neglected tropical diseases and other infections. Several cardiac implications of these infections have been reported but have not yet been validated by robust population data. This is in part due to limited access to health care and insufficient data collection infrastructure in many LMICs. Therefore, the true impact of these infections on the cardiovascular system may be underestimated, because of both underdiagnosis and underreporting bias. There is an urgent need to thoroughly delineate the cardiac impact of these conditions with elevated prevalence in LMICs and to propose strategies to reduce the negative consequences of these diseases in health systems with limited resources.
Collapse
|
5
|
Sliwa K, Viljoen CA, Hasan B, Ntusi NAB. Nutritional Heart Disease and Cardiomyopathies: JACC Focus Seminar 4/4. J Am Coll Cardiol 2022; 81:S0735-1097(22)07308-9. [PMID: 36599756 DOI: 10.1016/j.jacc.2022.08.812] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 08/24/2022] [Indexed: 01/03/2023]
Abstract
This JACC Focus Seminar provides an overview of and highlights recently published research on cardiomyopathies and nutritional heart disease that have a higher prevalence in tropical regions. The development of tropical cardiomyopathies and nutritional cardiovascular disease (CVD) is complicated by high rates of poverty, fragmented health care systems, and suboptimal access to health care because of socioeconomic inequalities, leading to the fact that children, adolescents, and young adults are disproportionally affected. Such tropical cardiomyopathies and nutritional CVD that have not been prevalent in high-income countries in the past decades are now reemerging. When treating migrants or refugees, it is important for attending physicians to consider the burden of endemic diseases in the countries of origin and the likelihood that such patients might be affected. In this review, the authors propose an approach for adequate diagnostic work-up leading to appropriate care for those with suspected or confirmed tropical cardiomyopathies and nutritional CVD.
Collapse
Affiliation(s)
- Karen Sliwa
- Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Division of Cardiology, Department of Medicine, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
| | - Charle Andre Viljoen
- Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Division of Cardiology, Department of Medicine, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Babar Hasan
- Division of Cardio-Thoracic Sciences, Sindh Institute of Urology and Transplant, Karachi, Pakistan
| | - Ntobeko A B Ntusi
- Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Division of Cardiology, Department of Medicine, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; South African Medical Research Council Extramural Unit on Intersection of Noncommunicable Diseases and Infectious Diseases, Cape Town, South Africa
| |
Collapse
|
6
|
Nyangulu W, Sadimba C, Nyirenda J, Twaibu G, Kamwendo J, Chawawa K, Masano A, Chilinda E, Kayuni S, Muula AS, Maleta K. The prevalence of Schistosoma mansoni infection among adults with chronic non-communicable diseases in Malawi. Trop Med Health 2022; 50:56. [PMID: 35986382 PMCID: PMC9389769 DOI: 10.1186/s41182-022-00450-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 08/12/2022] [Indexed: 11/10/2022] Open
Abstract
Background Schistosomiasis is a parasitic infectious disease caused by flatworms of the Schistosoma genus. The global burden of schistosomiasis is high. In Malawi, schistosomiasis is among the top 20 causes of outpatient department visits in health facilities. Schistosomiasis is among the most important but neglected causes of non-communicable diseases (NCD) peculiar to tropical endemic settings. While much is known about the contribution of S. haematobium to the NCD burden in Malawi, the role of S. mansoni remains largely unknown.
Methods We conducted a cross-sectional study at Mangochi District Hospital. Adults over 18 years diagnosed with NCDs (n = 414), admitted or attending weekly outpatient clinics were recruited between August 2021 and February 2022. Data were collected on sociodemographic characteristics, medical history, body weight, blood pressure, and fasting blood glucose. Stool and midstream urine were collected for Kato–Katz (KK) microscopy and urine point of care-circulating cathodic antigen (POC-CCA) tests, respectively. We computed prevalence of S. mansoni as number of positive KK and CCA tests, each divided by total submitted samples. Univariate and multivariable logistic regression were done to evaluate risk factors of NCDs and association between S. mansoni infection and NCDs. Results We recruited 414 participants, mean age 57 years (SD 16), 67% of whom were female. Prevalence of S. mansoni based on urine CCA was 15% (95% CI: 11–19) and 0% on KK microscopy. Hypertension was the most common condition with a prevalence of 85% (95% CI: 81–89), followed by diabetes mellitus with a prevalence of 42% (95% CI: 37–46) and heart disease with a prevalence of 3% (95% CI: 2–5). S. mansoni infection was not significantly associated with hypertension (OR: 1.2, 95% CI: 0.5–3.1), diabetes (OR: 0.6, 95% CI: 0.3–1.10) or heart disease (OR: 2.0, 95% CI: 0.4–10). Conclusions We observed moderate prevalence of S. mansoni infection among adults in the study per WHO classification of endemicity. This is within the range observed in children in Mangochi from 10 to 56.7%. Supplementary Information The online version contains supplementary material available at 10.1186/s41182-022-00450-3.
Collapse
|
7
|
Montera MW, Marcondes-Braga FG, Simões MV, Moura LAZ, Fernandes F, Mangine S, Oliveira Júnior ACD, Souza ALADAGD, Ianni BM, Rochitte CE, Mesquita CT, de Azevedo Filho CF, Freitas DCDA, Melo DTPD, Bocchi EA, Horowitz ESK, Mesquita ET, Oliveira GH, Villacorta H, Rossi Neto JM, Barbosa JMB, Figueiredo Neto JAD, Luiz LF, Hajjar LA, Beck-da-Silva L, Campos LADA, Danzmann LC, Bittencourt MI, Garcia MI, Avila MS, Clausell NO, Oliveira NAD, Silvestre OM, Souza OFD, Mourilhe-Rocha R, Kalil Filho R, Al-Kindi SG, Rassi S, Alves SMM, Ferreira SMA, Rizk SI, Mattos TAC, Barzilai V, Martins WDA, Schultheiss HP. Brazilian Society of Cardiology Guideline on Myocarditis - 2022. Arq Bras Cardiol 2022; 119:143-211. [PMID: 35830116 PMCID: PMC9352123 DOI: 10.36660/abc.20220412] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
| | - Fabiana G Marcondes-Braga
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil
| | - Marcus Vinícius Simões
- Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, São Paulo, SP - Brasil
| | | | - Fabio Fernandes
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil
| | - Sandrigo Mangine
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil
| | | | | | - Bárbara Maria Ianni
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil
| | - Carlos Eduardo Rochitte
- Instituto do Coração (InCor) - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil.,Hospital do Coração (HCOR), São Paulo, SP - Brasil
| | - Claudio Tinoco Mesquita
- Hospital Pró-Cardíaco, Rio de Janeiro, RJ - Brasil.,Universidade Federal Fluminense,Rio de Janeiro, RJ - Brasil.,Hospital Vitória, Rio de Janeiro, RJ - Brasil
| | | | | | | | - Edimar Alcides Bocchi
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil
| | | | - Evandro Tinoco Mesquita
- Universidade Federal Fluminense,Rio de Janeiro, RJ - Brasil.,Centro de Ensino e Treinamento Edson de Godoy Bueno / UHG, Rio de Janeiro, RJ - Brasil
| | | | | | | | | | | | | | - Ludhmila Abrahão Hajjar
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil.,Instituto do Câncer do Estado de São Paulo da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil
| | - Luis Beck-da-Silva
- Hospital de Clínicas de Porto Alegre, Porto Alegre, RS - Brasil.,Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS - Brasil
| | | | | | - Marcelo Imbroise Bittencourt
- Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ - Brasil.,Hospital Universitário Pedro Ernesto, Rio de Janeiro, RJ - Brasil
| | - Marcelo Iorio Garcia
- Hospital Universitário Clementino Fraga Filho (HUCFF) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ - Brasil
| | - Monica Samuel Avila
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil
| | | | | | | | | | | | | | - Sadeer G Al-Kindi
- Harrington Heart and Vascular Institute, University Hospitals and Case Western Reserve University,Cleveland, Ohio - EUA
| | | | - Silvia Marinho Martins Alves
- Pronto Socorro Cardiológico de Pernambuco (PROCAPE), Recife, PE - Brasil.,Universidade de Pernambuco (UPE), Recife, PE - Brasil
| | - Silvia Moreira Ayub Ferreira
- Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP - Brasil
| | - Stéphanie Itala Rizk
- Instituto do Câncer do Estado de São Paulo da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil.,Hospital Sírio Libanês, São Paulo, SP - Brasil
| | | | - Vitor Barzilai
- Instituto de Cardiologia do Distrito Federal, Brasília, DF - Brasil
| | - Wolney de Andrade Martins
- Universidade Federal Fluminense,Rio de Janeiro, RJ - Brasil.,DASA Complexo Hospitalar de Niterói, Niterói, RJ - Brasil
| | | |
Collapse
|
8
|
Miranda-Arboleda AF, González-Barrera LG, Liblik K, Farina J, Zaidel EJ, Saldarriaga C, Zhou Z, Al-Rawi R, López-López JP, Juarez-Lloclla JP, Gupta S, Prabhakaran D, Kumar RK, Sosa-Liprandi Á, Baranchuk A. Neglected Tropical Diseases and Sudden Cardiac Death: The NET-Heart Project. Rev Cardiovasc Med 2022; 23:254. [PMID: 39076906 PMCID: PMC11266773 DOI: 10.31083/j.rcm2307254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 05/25/2022] [Accepted: 06/06/2022] [Indexed: 07/31/2024] Open
Abstract
Sudden cardiac death (SCD) is responsible for approximately 6% of global mortality and 25% of cardiovascular (CV) deaths. SCD has been traditionally linked to coronary artery disease, valvular heart disease, cardiomyopathies, and genetic arrhythmia disorders. However, advancements in care for these diseases have not translated to a proportional reduction in SCD. This suggests an important role of underrecognized contributing pathologies. Neglected tropical diseases (NTDs) are a group of illnesses prevalent in tropical and sub-tropical regions which have been understudied partially due to their high prevalence in marginalized populations. The relationship between SCD and Chagas disease has been well-established, though emerging literature suggests that other NTDs with CV involvement may lead to fatal arrhythmias. Additionally, specific therapies for a subset of NTDs put patients at increased risk of malignant arrhythmias and other cardiac complications. This review aims to summarize the association between a group of selected NTDs and SCD.
Collapse
Affiliation(s)
- Andrés F. Miranda-Arboleda
- Division of Cardiology, Kingston Health Science Centre, Queen’s University, Kingston, ON K7L 2V7, Canada
- Cardiology Department, Pablo Tobón Uribe Hospital, 050034 Medellín, Colombia
| | | | - Kiera Liblik
- Department of Medicine, Translational Medicine, Queen’s University, Kingston, ON K7L 2V7, Canada
| | - Juan Farina
- Department of Cardiovascular and Thoracic Surgery, Mayo Clinic, Phoenix, AZ 85054, USA
| | - Ezequiel José Zaidel
- Cardiology Department, Sanatorio Güemes, and School of Medicine, University of Buenos Aires, C1180AAX Buenos Aires, Argentina
| | - Clara Saldarriaga
- Cardiology Service, Clínica CardioVID, Universidad de Antioquia, 050034 Medellín, Colombia
| | - Zier Zhou
- Atherosclerosis, Genomics and Vascular Biology Division, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada
| | - Reem Al-Rawi
- Department of Medicine, Queen's University, Kingston, ON K7L 2V7, Canada
| | - José Patricio López-López
- Cardiology Unit, Hospital Universitario San Ignacio/Pontificia Universidad Javeriana, 110231 Bogotá, Colombia
- Instituto Masira, Universidad de Santander, 680008 Bucaramanga, Colombia
| | | | - Shyla Gupta
- Faculty of Health Sciences, Queen’s University, Kingston, ON K7L 2V7, Canada
| | - Dorairaj Prabhakaran
- Centre for Chronic Conditions and Injuries, Public Health Foundation of India, 122002 Gurugram, India
- London School of Hygiene and Tropical Medicine, WC1E 7HT London, UK
| | - R Krishna Kumar
- Amrita Institute of Medical Sciences and Research Centre, Cochin, 682041 Kerala, India
| | - Álvaro Sosa-Liprandi
- Cardiology Department, Sanatorio Güemes, and School of Medicine, University of Buenos Aires, C1180AAX Buenos Aires, Argentina
| | - Adrian Baranchuk
- Division of Cardiology, Kingston Health Science Centre, Queen’s University, Kingston, ON K7L 2V7, Canada
| |
Collapse
|
9
|
Nunes MCP, Buss LF, Silva JLP, Martins LNA, Oliveira CDL, Cardoso CS, Brito BODF, Ferreira AM, Oliveira LC, Bierrenbach AL, Fernandes F, Busch MP, Hotta VT, Martinelli LMB, Soeiro MCFA, Brentegani A, Salemi VMC, Menezes MM, Ribeiro ALP, Sabino EC. Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up of Trypanosoma cruzi-Seropositive Individuals. Circulation 2021; 144:1553-1566. [PMID: 34565171 DOI: 10.1161/circulationaha.121.055112] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND There are few contemporary cohorts of Trypanosoma cruzi-seropositive individuals, and the basic clinical epidemiology of Chagas disease is poorly understood. Herein, we report the incidence of cardiomyopathy and death associated with T. cruzi seropositivity. METHODS Participants were selected in blood banks at 2 Brazilian centers. Cases were defined as T. cruzi-seropositive blood donors. T. cruzi-seronegative controls were matched for age, sex, and period of donation. Patients with established Chagas cardiomyopathy were recruited from a tertiary outpatient service. Participants underwent medical examination, blood collection, ECG, and echocardiogram at enrollment (2008-2010) and at follow-up (2018-2019). The primary outcomes were all-cause mortality and development of cardiomyopathy, defined as the presence of a left ventricular ejection fraction <50% or QRS complex duration ≥120 ms, or both. To handle loss to follow-up, a sensitivity analysis was performed using inverse probability weights for selection. RESULTS We enrolled 499 T. cruzi-seropositive donors (age 48±10 years, 52% male), 488 T. cruzi-seronegative donors (age 49±10 years, 49% male), and 101 patients with established Chagas cardiomyopathy (age 48±8 years, 59% male). The mortality in patients with established cardiomyopathy was 80.9 deaths/1000 person-years (py) (54/101, 53%) and 15.1 deaths/1000 py (17/114, 15%) in T. cruzi-seropositive donors with cardiomyopathy at baseline. Among T. cruzi-seropositive donors without cardiomyopathy at baseline, mortality was 3.7 events/1000 py (15/385, 4%), which was no different from T. cruzi-seronegative donors with 3.6 deaths/1000 py (17/488, 3%). The incidence of cardiomyopathy in T. cruzi-seropositive donors was 13.8 (95% CI, 9.5-19.6) events/1000 py (32/262, 12%) compared with 4.6 (95% CI, 2.3-8.3) events/1000 py (11/277, 4%) in seronegative controls, with an absolute incidence difference associated with T. cruzi seropositivity of 9.2 (95% CI, 3.6-15.0) events/1000 py. T. cruzi antibody level at baseline was associated with development of cardiomyopathy (adjusted odds ratio, 1.4 [95% CI, 1.1-1.8]). CONCLUSIONS We present a comprehensive description of the natural history of T. cruzi seropositivity in a contemporary patient population. The results highlight the central importance of anti-T. cruzi antibody titer as a marker of Chagas disease activity and risk of progression.
Collapse
Affiliation(s)
- Maria Carmo P Nunes
- Hospital das Clínicas and Faculdade de Medicina (M.C.P.N., B.O.d.F.B., A.L.P.R.), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Lewis F Buss
- Instituto de Medicina Tropical e Departamento de Moléstias Infecciosas e Parasitarias (L.F.B., E.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Jose Luiz P Silva
- Department of Statistics, Universidade Federal do Paraná, Curitiba, Brazil (J.L.P.S.)
| | - Larissa Natany A Martins
- Department of Statistics, Instituto de Ciências Exatas (L.N.A.M.), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | | | | | - Bruno Oliveira de Figueiredo Brito
- Hospital das Clínicas and Faculdade de Medicina (M.C.P.N., B.O.d.F.B., A.L.P.R.), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Ariela Mota Ferreira
- Health Science Program, Universidade Estadual de Montes Claros, Brazil (A.M.F., M.M.M.)
| | - Lea Campos Oliveira
- Laboratório de Investigação Médica (LIM03), Hospital das Clinicas (L.C.O.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Ana Luiza Bierrenbach
- Research and Education Institute, Hospital Sírio-Libanês, São Paulo, Brazil (A.L.B.)
| | - Fabio Fernandes
- Instituto do Coração (F.F., V.T.H., L.M.B.M., M.C.F.A.S., A.B., V.M.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Michael P Busch
- Blood Systems Research Institute, San Francisco, CA (M.P.B.)
| | - Viviane Tiemi Hotta
- Instituto do Coração (F.F., V.T.H., L.M.B.M., M.C.F.A.S., A.B., V.M.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Luiz Mario Baptista Martinelli
- Instituto do Coração (F.F., V.T.H., L.M.B.M., M.C.F.A.S., A.B., V.M.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Maria Carolina F Almeida Soeiro
- Instituto do Coração (F.F., V.T.H., L.M.B.M., M.C.F.A.S., A.B., V.M.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Adriana Brentegani
- Instituto do Coração (F.F., V.T.H., L.M.B.M., M.C.F.A.S., A.B., V.M.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Vera M C Salemi
- Instituto do Coração (F.F., V.T.H., L.M.B.M., M.C.F.A.S., A.B., V.M.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| | - Marcia M Menezes
- Health Science Program, Universidade Estadual de Montes Claros, Brazil (A.M.F., M.M.M.)
| | - Antonio Luiz P Ribeiro
- Hospital das Clínicas and Faculdade de Medicina (M.C.P.N., B.O.d.F.B., A.L.P.R.), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Ester Cerdeira Sabino
- Instituto de Medicina Tropical e Departamento de Moléstias Infecciosas e Parasitarias (L.F.B., E.C.S.), Faculdade de Medicina da Universidade de São Paulo, Brazil
| |
Collapse
|
10
|
Figtree GA, Broadfoot K, Casadei B, Califf R, Crea F, Drummond GR, Freedman JE, Guzik TJ, Harrison D, Hausenloy DJ, Hill JA, Januzzi JL, Kingwell BA, Lam CSP, MacRae CA, Misselwitz F, Miura T, Ritchie RH, Tomaszewski M, Wu JC, Xiao J, Zannad F. A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation 2021; 144:159-169. [PMID: 33876947 DOI: 10.1161/cir.0000000000000981] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic "buckets." Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased "omic" approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.
Collapse
Affiliation(s)
- Gemma A Figtree
- Kolling Institute, Royal North Shore Hospital, University of Sydney, Australia (G.A.F.)
| | - Keith Broadfoot
- Clinical Committee, National Heart Foundation of Australia (K.B.)
| | - Barbara Casadei
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK (B.C.)
- NIHR Oxford Biomedical Research Centre, UK (B.C.)
- British Heart Foundation Centre of Research Excellence, Oxford, UK (B.C.)
| | | | | | - Grant R Drummond
- Centre for Cardiovascular Biology and Disease Research and Department of Physiology, Anatomy and Microbiology, La Trobe University, Melbourne, Australia (G.R.D.)
| | - Jane E Freedman
- Cardiovascular Research, University of Massachusetts Medical School, Worcester (J.E.F.)
| | - Tomasz J Guzik
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK (T.J.G.)
- Jagiellonian University Collegium Medicum, Krakow, Poland (T.J.G.)
| | - David Harrison
- Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN (D.H.)
| | - Derek J Hausenloy
- Signature Research Program in Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore NUS Medical School (D.J.H.)
- National Heart Research Institute Singapore, National Heart Centre (D.J.H.)
- Yong Loo Lin School of Medicine, National University Singapore (D.J.H.)
- The Hatter Cardiovascular Institute, University College London, UK (D.J.H.)
- Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan (D.J.H.)
| | | | - James L Januzzi
- Massachusetts General Hospital, Harvard University, Boston (J.L.J.)
| | | | - Carolyn S P Lam
- National Heart Centre Singapore and Duke-National University of Singapore (C.S.P.L.)
| | - Calum A MacRae
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.A.M.)
| | | | - Tetsuji Miura
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, Japan (T.M.)
| | - Rebecca H Ritchie
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), VIC, Australia (R.H.R.)
| | - Maciej Tomaszewski
- Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health and Manchester University NHS Foundation Trust, University of Manchester, UK (M.T.)
| | - Joseph C Wu
- Stanford Cardiovascular Institute, CA (J.C.W.)
| | - Junjie Xiao
- Cardiac Regeneration and Ageing Laboratory, Institute of Cardiovascular Sciences, School of Life Sciences, Shanghai University, China (J.X.)
| | - Faiez Zannad
- Universite´ de Lorraine, INSERM CIC 1493, INI CRCT, CHRU, Nancy, France (F.Z.)
| |
Collapse
|
11
|
Figtree GA, Broadfoot K, Casadei B, Califf R, Crea F, Drummond GR, Freedman JE, Guzik TJ, Harrison D, Hausenloy DJ, Hill JA, Januzzi JL, Kingwell BA, Lam CSP, MacRae CA, Misselwitz F, Miura T, Ritchie RH, Tomaszewski M, Wu JC, Xiao J, Zannad F. A call to action for new global approaches to cardiovascular disease drug solutions. Eur Heart J 2021; 42:1464-1475. [PMID: 33847746 DOI: 10.1093/eurheartj/ehab068] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Revised: 01/01/2021] [Accepted: 02/05/2021] [Indexed: 12/12/2022] Open
Abstract
Whilst we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic 'buckets'. Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased 'omic' approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.
Collapse
Affiliation(s)
- Gemma A Figtree
- Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia
| | | | - Barbara Casadei
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- NIHR Oxford Biomedical Research Centre, Oxford, UK
- British Heart Foundation Centre of Research Excellence, Oxford, UK
| | | | | | - Grant R Drummond
- Centre for Cardiovascular Biology and Disease Research; and Department of Physiology, Anatomy and Microbiology, La Trobe University, Melbourne, Australia
| | - Jane E Freedman
- Cardiovascular Research, University of Massachusetts Medical School, MA, USA
| | - Tomasz J Guzik
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK and Jagiellonian University Collegium Medicum, Krakow, Poland
| | - David Harrison
- Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Derek J Hausenloy
- Signature Research Program in Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore NUS Medical School, Singapore
- National Heart Research Institute Singapore, National Heart Centre, Singapore
- Yong Loo Lin School of Medicine, National University Singapore, Singapore
- The Hatter Cardiovascular Institute, University College London, London, UK
- Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan
| | | | - James L Januzzi
- Massachusetts General Hospital, Harvard University, Boston, MA, USA
| | | | - Carolyn S P Lam
- National Heart Centre Singapore and Duke-National University of Singapore
| | - Calum A MacRae
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Tetsuji Miura
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, Sapporo, Japan
| | - Rebecca H Ritchie
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, VIC, Australia
| | - Maciej Tomaszewski
- Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health and Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK
| | - Joseph C Wu
- Stanford Cardiovascular Institute, Stanford, CA, USA
| | - Junjie Xiao
- Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, School of Life Sciences, Shanghai University, Shanghai, 200444, China
| | - Faiez Zannad
- Université de Lorraine, INSERM CIC 1493, INI CRCT, CHRU Nancy, France
| |
Collapse
|
12
|
Virtual Screening Based on QSAR and Molecular Docking of Possible Inhibitors Targeting Chagas CYP51. J CHEM-NY 2021. [DOI: 10.1155/2021/6640624] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Chagas is a neglected tropical disease caused by the parasite Trypanosoma cruzi with no effective treatment in all its forms. There is a need to find more effective therapeutic alternatives with reduced toxicity. In this contribution, multiple linear regression models were used to identify the molecular descriptors that best describe the inhibitory activity of 52 fenarimol analogues against Trypanosoma cruzi. The topological, physicochemical, thermodynamic, electronic, and charge descriptors were evaluated to cover a wide range of properties that frequently encode biological activity. A model with high predictive value was obtained based on geometrical descriptors and descriptors encoding hydrophobicity and London dispersion forces as necessary for the inhibition of Trypanosoma cruzi-CYP51. Docking methodology was implemented to evaluate molecular interactions in silico. The virtual screening results in this study can be used for rational design of new analogues with improved activity against Chagas disease.
Collapse
|
13
|
Bukhman G, Mocumbi AO, Atun R, Becker AE, Bhutta Z, Binagwaho A, Clinton C, Coates MM, Dain K, Ezzati M, Gottlieb G, Gupta I, Gupta N, Hyder AA, Jain Y, Kruk ME, Makani J, Marx A, Miranda JJ, Norheim OF, Nugent R, Roy N, Stefan C, Wallis L, Mayosi B. The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion. Lancet 2020; 396:991-1044. [PMID: 32941823 PMCID: PMC7489932 DOI: 10.1016/s0140-6736(20)31907-3] [Citation(s) in RCA: 153] [Impact Index Per Article: 38.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 05/29/2020] [Accepted: 08/25/2020] [Indexed: 12/14/2022]
Affiliation(s)
- Gene Bukhman
- Department of Global Health and Social Medicine, Harvard University, Boston, MA, USA; Program in Global NCDs and Social Change, Harvard University, Boston, MA, USA; Partners In Health, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
| | - Ana O Mocumbi
- Universidade Eduardo Mondlane, Maputo, Mozambique; Instituto Nacional de Saúde, Maputo, Mozambique
| | - Rifat Atun
- Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA
| | - Anne E Becker
- Department of Global Health and Social Medicine, Harvard University, Boston, MA, USA
| | - Zulfiqar Bhutta
- Center for Global Child Health, Hospital for Sick Kids, Toronto, ON, Canada; Centre of Excellence in Women and Child Health, Aga Khan University, Karachi, Pakistan; Institute for Global Health & Development, Aga Khan University, South-Central Asia, East Africa, and UK
| | | | - Chelsea Clinton
- Clinton Foundation, New York, NY, USA; Mailman School of Public Health, Columbia University, New York, NY, USA
| | - Matthew M Coates
- Department of Global Health and Social Medicine, Harvard University, Boston, MA, USA; Program in Global NCDs and Social Change, Harvard University, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | | | - Majid Ezzati
- MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK
| | - Gary Gottlieb
- Department of Psychiatry, Harvard Medical School, Harvard University, Boston, MA, USA
| | - Indrani Gupta
- Health Policy Research Unit, Institute of Economic Growth, Delhi, India
| | - Neil Gupta
- Department of Global Health and Social Medicine, Harvard University, Boston, MA, USA; Program in Global NCDs and Social Change, Harvard University, Boston, MA, USA; Partners In Health, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - Adnan A Hyder
- Milken Institute School of Public Health, George Washington University, Washington, DC, USA
| | - Yogesh Jain
- Jan Swasthya Sahyog, Bilaspur, Chhattisgarh, India
| | - Margaret E Kruk
- Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA
| | - Julie Makani
- Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
| | - Andrew Marx
- Department of Global Health and Social Medicine, Harvard University, Boston, MA, USA; Program in Global NCDs and Social Change, Harvard University, Boston, MA, USA
| | - J Jaime Miranda
- CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Ole F Norheim
- Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
| | - Rachel Nugent
- Research Triangle Institute International, Seattle, WA, USA
| | - Nobhojit Roy
- WHO Collaborating Centre for Research on Surgical Care Delivery in LMICs, Department of Surgery, BARC Hospital, HBNI University, Government of India, Mumbai, India; Field Health Systems Laboratory, Bihar Technical Support Programme, CARE India, Madhubani, Bihar, India
| | - Cristina Stefan
- SingHealth Duke-NUS Global Health Institute (SDGHI), Duke-NUS Medical School, Singapore; African Medical Research and Innovation Institute, Cape Town, South Africa
| | - Lee Wallis
- Division of Emergency Medicine, University of Cape Town, Cape Town, South Africa
| | - Bongani Mayosi
- Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| |
Collapse
|
14
|
Neglected Tropical Diseases and Other Infectious Diseases Affecting the Heart. The NET-Heart Project: Rationale and Design. Glob Heart 2020; 15:60. [PMID: 32923353 PMCID: PMC7473196 DOI: 10.5334/gh.867] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Introduction Neglected tropical diseases (NTDs) are a group of infections that are prevalent in many of the tropical and sub-tropical developing countries where poverty is rampant. NTDs have remained largely unnoticed in the global health agenda. There is a substantial gap between the burden of disease for NTDs in cardiovascular diseases (CVD) and research devoted to the affected populations. We created a Latin-American initiative with emerging leaders (EL) from the Interamerican Society of Cardiology (IASC) with the objective to perform multiple systematic reviews of NTDs and other infectious diseases affecting the heart: The NET-Heart Project. Objective To describe the rationale and design considerations of the NET-Heart project. Methods The NET-Heart Project is a collaborative work of the IASC EL program. The main objective of the NET-Heart project is to systematically evaluate the available evidence of NTDs and other infectious diseases and their cardiovascular involvement. As a secondary objective, this initiative aims to offer recommendations and potential diagnostic and therapeutic algorithms that can aid the management of cardiovascular complications of these infectious diseases. After an expert discussion 17 initial infectious diseases were selected, for each disease we created one working group. The project was structured in different phases: Systematic review, brainstorming workshops, analysis and results, manuscript writing and recommendations and evaluation of clinical implications. Conclusion The NET-Heart project is an innovative collaborative initiative created to assess burden and impact of NTDs and other infectious diseases in CVD. NTDs can no longer be ignored and must be prioritised on the health and research agenda. This project aims to review in depth the evidence regarding cardiac compromise of these serious conditions and to propose strategies to overcome barriers for efficient diagnosis and treatment of cardiovascular complications.
Collapse
|
15
|
Chatelain E, Scandale I. Animal models of Chagas disease and their translational value to drug development. Expert Opin Drug Discov 2020; 15:1381-1402. [PMID: 32812830 DOI: 10.1080/17460441.2020.1806233] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
INTRODUCTION American trypanosomiasis, better known as Chagas disease, is a global public health issue. Current treatments targeting the causative parasite, Trypanosoma cruzi, are limited to two old nitroheterocyclic compounds; new, safer drugs are needed. New tools to identify compounds suitable for parasitological cure in humans have emerged through efforts in drug discovery. AREAS COVERED Animal disease models are an integral part of the drug discovery process. There are numerous experimental models of Chagas disease described and in use; rather than going through each of these and their specific features, the authors focus on developments in recent years, in particular the imaging technologies that have dramatically changed the Chagas R&D landscape, and provide a critical view on their value and limitations for moving compounds forward into further development. EXPERT OPINION The application of new technological advances to the field of drug development for Chagas disease has led to the implementation of new and robust/standardized in vivo models that contributed to a better understanding of host/parasite interactions. These new models should also build confidence in their translational value for moving compounds forward into clinical development.
Collapse
Affiliation(s)
- Eric Chatelain
- R&D Department, Drugs for Neglected Diseases Initiative (DNDi) , Geneva, Switzerland
| | - Ivan Scandale
- R&D Department, Drugs for Neglected Diseases Initiative (DNDi) , Geneva, Switzerland
| |
Collapse
|
16
|
Zaki P, Domingues EL, Amjad FM, Narde MB, Gonçalves KR, Viana ML, de Paula H, de Lima WG, Huang H, Bahia MT, Sherer PE, Dos Santos FM, Weiss LM, Tanowitz HB. The role of fat on cardiomyopathy outcome in mouse models of chronic Trypanosoma cruzi infection. Parasitol Res 2020; 119:1829-1843. [PMID: 32206887 DOI: 10.1007/s00436-020-06645-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 02/28/2020] [Indexed: 10/24/2022]
Abstract
The underlying pathogenic mechanisms of cardiomyopathy in Chagas disease are still unsolved. In order to better clarify the role of fat on the evolution of cardiomyopathy, the present study employed three murine models of chronic Trypanosoma cruzi infection: (1) aP2-RIDα/β transgenic mice (RID mice; an adipose tissue model which express a gain-of-function potent anti-inflammatory activity), (2) allograft inflammatory factor-1 knockout mice (Aif1-/-), and (3) a Swiss outbred mice. RID mice and non-transgenic mice (wild type, WT) were infected with blood trypomastigotes of Brazil strain. During the acute stage of infection, RID mice had lower parasitemia, lower heart inflammation, and a decrease in the relative distribution of parasite load from cardiac muscle tissue toward epididymal fat. Nevertheless, comparable profiles of myocardial inflammatory infiltrates and relative distribution of parasite load were observed among RID and WT at the chronic stage of infection. Aif1-/- and Aif1+/+ mice were infected with bloodstream trypomastigotes of Tulahuen strain and fed with high-fat diet (HFD) or regular diet (RD). Interestingly, Aif1+/+ HFD infected mice showed the highest mortality. Swiss mice infected with blood trypomastigotes of Berenice-78 strain on a HFD had higher levels of TNFα and more inflammation in their heart tissue than infected mice fed a RD. These various murine models implicate adipocytes in the pathogenesis of chronic Chagas disease and suggest that HFD can lead to a significant increase in the severity of parasite-induced chronic cardiac damage. Furthermore, these data implicate adipocyte TLR4-, TNFα-, and IL-1β-mediated signaling in pro-inflammatory pathways and Aif-1 gene expression in the development of chronic Chagas disease.
Collapse
Affiliation(s)
- Paul Zaki
- Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA
| | - Elisa Lbc Domingues
- Department of Pharmacy and Nutrition, Federal University of Espírito Santo, Guararema, Alegre, ES, 29500-000, Brazil
| | - Farhad M Amjad
- Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA
| | - Maiara B Narde
- Department of Pharmacy and Nutrition, Federal University of Espírito Santo, Guararema, Alegre, ES, 29500-000, Brazil
| | - Karolina R Gonçalves
- School of Medicine, Federal University of Ouro Preto, Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil
| | - Mirelle L Viana
- Department of Pharmacy and Nutrition, Federal University of Espírito Santo, Guararema, Alegre, ES, 29500-000, Brazil
| | - Heberth de Paula
- Department of Pharmacy and Nutrition, Federal University of Espírito Santo, Guararema, Alegre, ES, 29500-000, Brazil
| | - Wanderson G de Lima
- Department of Biological Sciences, Federal University of Ouro Preto, Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil
| | - Huan Huang
- Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA
| | - Maria T Bahia
- School of Medicine, Federal University of Ouro Preto, Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.,Department of Biological Sciences, Federal University of Ouro Preto, Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil
| | - Philipp E Sherer
- The Touchstone Diabetes Center, UT Southwestern Medical Center, 5323 Harry Blvd, Dallas, TX, 75390, USA
| | - Fabiane M Dos Santos
- Department of Pharmacy and Nutrition, Federal University of Espírito Santo, Guararema, Alegre, ES, 29500-000, Brazil
| | - Louis M Weiss
- Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. .,Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
| | - Herbert B Tanowitz
- Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.,Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA
| |
Collapse
|
17
|
de Carvalho FP, Azevedo CF. Comprehensive Assessment of Endomyocardial Fibrosis with Cardiac MRI: Morphology, Function, and Tissue Characterization. Radiographics 2020; 40:336-353. [PMID: 32004118 DOI: 10.1148/rg.2020190148] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Endomyocardial fibrosis (EMF) affects approximately 12 million persons worldwide and is an important cause of restrictive cardiomyopathy in the developing world, with the highest prevalence reported in sub-Saharan Africa, South Asia, and South America. EMF is characterized by apical filling with fibrotic tissue of one or both ventricles, often associated with thrombus, calcification, and atrioventricular valve regurgitation, leading to typical symptoms of restrictive heart failure. Transthoracic echocardiography (TTE) is the first-line modality for assessment of EMF, basically owing to its widespread availability. However, in recent years cardiac MRI has emerged as a powerful tool for assessment of cardiac morphology and function, with higher accuracy than TTE, along with the unique advantage of being able to provide comprehensive noninvasive tissue characterization. Delayed enhancement (DE) imaging is the cornerstone of cardiac MRI tissue characterization and allows accurate identification of myocardial fibrosis, conveying valuable additional diagnostic and prognostic information. The typical DE pattern in EMF, described as the "double V" sign, consists of a three-layered pattern of normal myocardium, thickened enhanced endomyocardium, and overlying thrombus at the apex of the affected ventricle; it has excellent correlation with histopathologic findings and plays an important role in differentiating EMF from other cardiomyopathies. Conversely, fibrous tissue deposition quantified using DE imaging, when indexed to body surface area, has been shown to be a strong independent predictor of mortality. The aim of this review is to summarize state-of-the-art applications of cardiac MRI for diagnostic and prognostic assessment of patients with suspected or confirmed EMF. Online supplemental material is available for this article. ©RSNA, 2020.
Collapse
Affiliation(s)
- Filipe Penna de Carvalho
- From Diagnósticos da America (DASA), Rio de Janeiro, Brazil (F.P.d.C., C.F.A.); Americas Serviços Médicos, Rio de Janeiro, Brazil (F.P.d.C.); and Division of Cardiology, Duke University Medical Center, Duke Medical Pavilion, 10 Medicine Circle, Room 1E63, DUMC 3934, Durham, NC 27710 (C.F.A.)
| | - Clerio Francisco Azevedo
- From Diagnósticos da America (DASA), Rio de Janeiro, Brazil (F.P.d.C., C.F.A.); Americas Serviços Médicos, Rio de Janeiro, Brazil (F.P.d.C.); and Division of Cardiology, Duke University Medical Center, Duke Medical Pavilion, 10 Medicine Circle, Room 1E63, DUMC 3934, Durham, NC 27710 (C.F.A.)
| |
Collapse
|
18
|
Carneiro ZA, Lima JC, Lopes CD, Gaspari APS, de Albuquerque S, Dinelli LR, Veloso-Silva LLW, Paganelli MO, Libardi SH, Oliveira CG, Deflon VM, Oliveira RJ, Borges JC, Maia PIS. Heterobimetallic nickel(II) and palladium(II) complexes derived from S-benzyl-N- (ferrocenyl)methylenedithiocarbazate: Trypanocidal activity and interaction with Trypanosoma cruzi Old Yellow Enzyme (TcOYE). Eur J Med Chem 2019; 180:213-223. [PMID: 31306908 DOI: 10.1016/j.ejmech.2019.07.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 06/10/2019] [Accepted: 07/04/2019] [Indexed: 10/26/2022]
Abstract
Reactions of Ni(II) and Pd(II) precursors with S-benzyl-N-(ferrocenyl)methylenedithiocarbazate (HFedtc) led to the formation of heterobimetallic complexes of the type [MII(Fedtc)2] (M = Ni and Pd). The characterization of the compounds involved the determination of melting point, FTIR, UV-Vis, 1H NMR, elemental analysis and electrochemical experiments. Furthermore, the crystalline structures of HFedtc and [NiII(Fedtc)2] were determined by single crystal X-ray diffraction. The compounds were evaluated against the intracellular form of Trypanosoma cruzi (Tulahuen Lac-Z strain) and the cytotoxicity assays were assessed using LLC-MK2 cells. The results showed that the coordination of HFedtc to Ni(II) or Pd(II) decreases the in vitro trypanocidal activity while the cytotoxicity against LLC-MK2 cells does not change significantly. [PdII(Fedtc)2] showed the greater potential between the two complexes studied, showing an SI value of 8.9. However, this value is not better than that of the free ligand with an SI of 40, a similar value to that of the standard drug benznidazole (SI = 48). Additionally, molecular docking simulations were performed with Trypanosoma cruzi Old Yellow Enzyme (TcOYE), which predicted that HFedtc binds to the protein, almost parallel to the flavin mononucleotide (FMN) prosthetic group, while the [NiII(Fedtc)2] complex was docked into the enzyme binding site in a significantly different manner. In order to confirm the hypothetical interaction, in vitro experiments of fluorescence quenching and enzymatic activity were performed which indicated that, although HFedtc was not processed by the enzyme, it was able to act as a competitive inhibitor, blocking the hydride transfer from the FMN prosthetic group of the enzyme to the menadione substrate.
Collapse
Affiliation(s)
- Zumira A Carneiro
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil
| | - Jackelinne C Lima
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Av. Dr. Randolfo Borges 1400, 38025-440, Uberaba, MG, Brazil
| | - Carla D Lopes
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil
| | - Ana P S Gaspari
- Instituto Federal do Paraná - Campus Paranavaí, Av. José Felipe Tequinha, 1400, 87703-536, Paranavaí, PR, Brazil
| | - Sergio de Albuquerque
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP-USP, Universidade de São Paulo, Avenida do Café s/n, 14040-903, Ribeirão Preto, SP, Brazil
| | - Luis R Dinelli
- Faculdade de Ciências Integrada do Pontal, Universidade Federal de Uberlândia, Rua vinte, 1600, 38304-402, Ituiutaba, MG, Brazil
| | - Laudimir L W Veloso-Silva
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Marcella O Paganelli
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Silvia H Libardi
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Carolina G Oliveira
- Instituto de Química, Universidade Federal de Uberlândia, Av. João Naves de Ávila 2121, 38400-902, Uberlândia, MG, Brazil
| | - Victor M Deflon
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Ronaldo J Oliveira
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Av. Dr. Randolfo Borges 1400, 38025-440, Uberaba, MG, Brazil
| | - Júlio C Borges
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, P.O. Box 780, 13560-970, Brazil
| | - Pedro I S Maia
- Núcleo de Desenvolvimento de Compostos Bioativos (NDCBio), Universidade Federal do Triângulo Mineiro, Av. Dr. Randolfo Borges 1400, 38025-440, Uberaba, MG, Brazil.
| |
Collapse
|
19
|
Philot Pavão B, Demarque KC, Meuser Batista M, Melo de Oliveira G, França da Silva C, Guedes da Silva FH, Gonçalves Caputo LF, Machado Cascabulho C, Barcinski MA, Correia Soeiro MDN. Impact of autologous whole blood administration upon experimental mouse models of acute Trypanosoma cruzi infection. J Venom Anim Toxins Incl Trop Dis 2018; 24:25. [PMID: 30186314 PMCID: PMC6117903 DOI: 10.1186/s40409-018-0157-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 08/01/2018] [Indexed: 01/03/2023] Open
Abstract
Background Autologous whole blood (AWB) administration is described as alternative/complementary medical practice widely employed in medical and veterinary therapy against infections, chronic pathologies and neoplasias. Our aim is to investigate in vivo biological effect of AWB using healthy murine models under the course of Trypanosoma cruzi acute infection. Methods The first set of studies consisted of injecting different volumes of AWB and saline (SAL) into the posterior region of quadriceps muscle of healthy male Swiss mice under distinct therapeutic schemes evaluating: animal behavior, body and organ weight, hemogram, plasmatic biochemical markers for tissue damage and inflammatory cytokine levels and profile. To assess the impact on the experimental T. cruzi infection, different schemes (prior and post infection) and periods of AWB administration (from one up to 10 days) were conducted, also employing heterologous whole blood (HWB) and evaluating plasma cytokine profile. Results No major adverse events were observed in healthy AWB-treated mice, except gait impairment in animals that received three doses of 20 μL AWB in the same hind limb. AWB and SAL triggered an immediate polymorphonuclear response followed by mononuclear infiltrate. Although SAL triggered an inflammatory response, the kinetics and intensity of the histological profile and humoral mediator levels were different from AWB, the latter occurring earlier and more intensely with concomitant elevation of plasma IL-6. Inflammatory peak response of SAL, mainly composed of mononuclear cells with IL-10, was increased at 24 h. According to the mouse model of acute T. cruzi infection, only minor decreases (< 30%) in the parasitemia levels were produced by AWB and HWB given before and after infection, without protecting against mortality. Rises in IFN-gamma, TNF-alpha and IL-6 were detected at 9 dpi in all infected animals as compared to uninfected mice but only Bz displayed a statistically significant diminution (p = 0.02) in TNF-alpha levels than infected and untreated mice. Conclusions This study revealed that the use of autologous whole blood (AWB) in the acute model employed was unable to reduce the parasitic load of infected mice, providing only a minor decrease in parasitemia levels (up to 30%) but without protecting against animal mortality. Further in vivo studies will be necessary to elucidate the effective impact of this procedure.
Collapse
Affiliation(s)
- Beatriz Philot Pavão
- 1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | - Kelly Cristina Demarque
- 1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | - Marcos Meuser Batista
- 1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | - Gabriel Melo de Oliveira
- 1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | - Cristiane França da Silva
- 1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | | | - Luzia Fátima Gonçalves Caputo
- 2Laboratório de Patologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | - Cynthia Machado Cascabulho
- 3Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | - Marcello André Barcinski
- 1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| | - Maria de Nazaré Correia Soeiro
- 1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ Brazil
| |
Collapse
|
20
|
Soko ND, Masimirembwa C, Dandara C. Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY 2018; 20:498-509. [PMID: 27631189 DOI: 10.1089/omi.2016.0114] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The incidence of cardiovascular diseases (CVDs) in African populations residing in the African continent is on the rise fueled by both a steady increase in CVD risk factors and comorbidities such as human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), tuberculosis, and parasitic diseases such as bilharzia. Statins are recommended together with lifestyle changes in the treatment of hypercholesterolemia and overall reduction of cardiovascular events. Rosuvastatin in particular is an attractive candidate in the management of CVDs in African populations often plagued with multimorbidities owing to both its potency and low drug-to-drug interaction potential. In this expert review, we describe the pharmacogenetics of rosuvastatin and how it may instrumentally affect the African populations. We describe polymorphisms in the candidate genes, ABCG2, SLCO1B1, CYP2C9, APOE, PCSK9, LDLR, LPA, and HMGCR, and their role in the potency and safety of rosuvastatin therapy. We report on qualitative and quantitative differences in the distribution of genetic variants that affect efficacy and toxicity of rosuvastatin. These differences are observed across world populations (Caucasian, European, and Asian) as well as within African populations. Finally, we advocate for extensive pharmacogenetic studies in African populations that take into account the genetic diversity of intra-African ethnic groups and the genetic differences between African populations and other global populations, with a collaborative and collective aim to provide effective and safe use of rosuvastatin in management of CVD in Africa. Our key thesis presented in this innovation field analysis is that rosuvastatin precision medicine can serve as a veritable Glocal (Global and Local) model to offer pharmacogenetic-guided optimal therapeutics for the public in both developing and developed regions of the world.
Collapse
Affiliation(s)
- Nyarai D Soko
- 1 Pharmacogenetics Research Group, Division of Human Genetics, Department of Pathology, Faculty of Health Sciences, and University of Cape Town , Cape Town, South Africa
| | - Collen Masimirembwa
- 2 African Institute of Biomedical Science and Technology (AiBST) , Wilkins Hospital, Harare, Zimbabwe .,3 Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town, South Africa
| | - Collet Dandara
- 1 Pharmacogenetics Research Group, Division of Human Genetics, Department of Pathology, Faculty of Health Sciences, and University of Cape Town , Cape Town, South Africa
| |
Collapse
|
21
|
Chatelain E, Ioset JR. Phenotypic screening approaches for Chagas disease drug discovery. Expert Opin Drug Discov 2017; 13:141-153. [PMID: 29235363 DOI: 10.1080/17460441.2018.1417380] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
INTRODUCTION Chagas disease, caused by the parasite Trypanosoma cruzi, is a global public health issue. Current treatments targeting the parasite are limited to two old nitroheterocyclic drugs with serious side effects. The need for new and safer drugs has prompted numerous drug discovery efforts to identify compounds suitable for parasitological cure in the last decade. Areas covered: Target-based drug discovery has been limited by the small number of well-validated targets - the latest example being the failure of azoles, T. cruzi CYP51 inhibitors, in proof-of-concept clinical trials; instead phenotypic-based drug discovery has become the main pillar of Chagas R&D. Rather than focusing on the technical features of these screening assays, the authors describe the different assays developed and available in the field, and provide a critical view on their values and limitations in the screening cascade for Chagas drug development. Expert opinion: The application of technological advances to the field of Chagas disease has led to a variety of phenotypic assays that have not only changed the disease discovery landscape but have also helped us to gain a better understanding of parasite/host interactions. Recent examples of target resolution from phenotypic hits will uncover new opportunities for drug discovery for Chagas disease.
Collapse
Affiliation(s)
- Eric Chatelain
- a Drugs for Neglected Diseases initiative (DNDi), R&D Department , Geneva , Switzerland
| | - Jean-Robert Ioset
- a Drugs for Neglected Diseases initiative (DNDi), R&D Department , Geneva , Switzerland
| |
Collapse
|
22
|
Eze IC, Esse C, Bassa FK, Koné S, Acka F, Yao L, Imboden M, Jaeger FN, Schindler C, Dosso M, Laubhouet-Koffi V, Kouassi D, N'Goran EK, Utzinger J, Bonfoh B, Probst-Hensch N. Côte d'Ivoire Dual Burden of Disease (CoDuBu): Study Protocol to Investigate the Co-occurrence of Chronic Infections and Noncommunicable Diseases in Rural Settings of Epidemiological Transition. JMIR Res Protoc 2017; 6:e210. [PMID: 29079553 PMCID: PMC5681722 DOI: 10.2196/resprot.8599] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Revised: 09/29/2017] [Accepted: 09/29/2017] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Individual-level concomitance of infectious diseases and noncommunicable diseases (NCDs) is poorly studied, despite the reality of this dual disease burden for many low- and middle-income countries (LMICs). OBJECTIVE This study protocol describes the implementation of a cohort and biobank aiming for a better understanding of interrelation of helminth and Plasmodium infections with NCD phenotypes like metabolic syndrome, hypertension, and diabetes. METHODS A baseline cross-sectional population-based survey was conducted over one year, in the Taabo health and demographic surveillance system (HDSS) in south-central Côte d'Ivoire. We randomly identified 1020 consenting participants aged ≥18 years in three communities (Taabo-Cité, Amani-Ménou, and Tokohiri) reflecting varying stages of epidemiological transition. Participants underwent health examinations consisting of NCD phenotyping (anthropometry, blood pressure, renal function, glycemia, and lipids) and infectious disease testing (infections with soil-transmitted helminths, schistosomes, and Plasmodium). Individuals identified to have elevated blood pressure, glucose, lipids, or with infections were referred to the central/national health center for diagnostic confirmation and treatment. Aliquots of urine, stool, and venous blood were stored in a biobank for future exposome/phenome research. In-person interviews on sociodemographic attributes, risk factors for infectious diseases and NCDs, medication, vaccinations, and health care were also conducted. Appropriate statistical techniques will be applied in exploring the concomitance of infectious diseases and NCDs and their determinants. Participants' consent for follow-up contact was obtained. RESULTS Key results from this baseline study, which will be published in peer-reviewed literature, will provide information on the prevalence and co-occurrence of infectious diseases, NCDs, and their risk factors. The Taabo HDSS consists of rural and somewhat more urbanized areas, allowing for comparative studies at different levels of epidemiological transition. An HDSS setting is ideal as a basis for longitudinal studies since their sustainable field work teams hold close contact with the local population. CONCLUSIONS The collaboration between research institutions, public health organizations, health care providers, and staff from the Taabo HDSS in this study assures that the synthesized evidence will feed into health policy towards integrated infectious disease-NCD management. The preparation of health systems for the dual burden of disease is pressing in low- and middle-income countries. The established biobank will strengthen the local research capacity and offer opportunities for biomarker studies to deepen the understanding of the cross-talk between infectious diseases and NCDs. TRIAL REGISTRATION International Standard Randomized Controlled Trials Number (ISRCTN): 87099939; http://www.isrctn.com/ISRCTN87099939 (Archived by WebCite at http://www.webcitation.org/6uLEs1EsX).
Collapse
Affiliation(s)
- Ikenna C Eze
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland.,Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire
| | - Clémence Esse
- Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire.,Institut d'Ethnosociologie, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire
| | - Fidèle K Bassa
- Unite de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire
| | - Siaka Koné
- Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire
| | - Felix Acka
- Institut National de Santé Publique, Abidjan, Côte d'Ivoire
| | - Loukou Yao
- Ligue Ivoirienne contre l'Hypertension Artérielle et les Maladies Cardiovasculaire, Abidjan, Côte d'Ivoire
| | - Medea Imboden
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | - Fabienne N Jaeger
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | - Christian Schindler
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | - Mireille Dosso
- Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire
| | - Véronique Laubhouet-Koffi
- Ligue Ivoirienne contre l'Hypertension Artérielle et les Maladies Cardiovasculaire, Abidjan, Côte d'Ivoire
| | - Dinard Kouassi
- Institut National de Santé Publique, Abidjan, Côte d'Ivoire
| | - Eliézer K N'Goran
- Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire.,Unite de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire
| | - Jürg Utzinger
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | - Bassirou Bonfoh
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland.,Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire
| | - Nicole Probst-Hensch
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| |
Collapse
|
23
|
Abstract
Cardiovascular diseases are widely distributed throughout the world. Human parasitic infections are ubiquitous. Tropical parasites are increasingly recognized as causes of cardiovascular diseases. In this review, we address the most frequently reported parasites that directly infect the myocardium, including Trypanosoma cruzi, the protozoal causative agent of American trypanosomiasis (Chagas disease), and Taenia solium, the cestode causative agent of taeniasis and cysticercosis. We also discuss tropical endomyocardial fibrosis, trichinellosis and schistosomiasis. Health systems, attitudes, the perceptions of both patients and physicians as well as socioeconomic factors should all be explored and recognized as crucial factors for improving the control of cardiovascular diseases in the tropics. Clinicians throughout the world must remain aware of imported parasites as potential causes of cardiac diseases.
Collapse
Affiliation(s)
- Zoe C Groom
- Costello Medical Consulting Limited, Cambridge
| | | | - Vasileios Zochios
- Department of Intensive Care Medicine, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
- College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| |
Collapse
|
24
|
Kwan GF, Mayosi BM, Mocumbi AO, Miranda JJ, Ezzati M, Jain Y, Robles G, Benjamin EJ, Subramanian SV, Bukhman G. Endemic Cardiovascular Diseases of the Poorest Billion. Circulation 2016; 133:2561-75. [PMID: 27297348 DOI: 10.1161/circulationaha.116.008731] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The poorest billion people are distributed throughout the world, though most are concentrated in rural sub-Saharan Africa and South Asia. Cardiovascular disease (CVD) data can be sparse in low- and middle-income countries beyond urban centers. Despite this urban bias, CVD registries from the poorest countries have long revealed a predominance of nonatherosclerotic stroke, hypertensive heart disease, nonischemic and Chagas cardiomyopathies, rheumatic heart disease, and congenital heart anomalies, among others. Ischemic heart disease has been relatively uncommon. Here, we summarize what is known about the epidemiology of CVDs among the world’s poorest people and evaluate the relevance of global targets for CVD control in this population. We assessed both primary data sources, and the 2013 Global Burden of Disease Study modeled estimates in the world’s 16 poorest countries where 62% of the population are among the poorest billion. We found that ischemic heart disease accounted for only 12% of the combined CVD and congenital heart anomaly disability-adjusted life years (DALYs) in the poorest countries, compared with 51% of DALYs in high-income countries. We found that as little as 53% of the combined CVD and congenital heart anomaly burden (1629/3049 DALYs per 100 000) was attributed to behavioral or metabolic risk factors in the poorest countries (eg, in Niger, 82% of the population among the poorest billion) compared with 85% of the combined CVD and congenital heart anomaly burden (4439/5199 DALYs) in high-income countries. Further, of the combined CVD and congenital heart anomaly burden, 34% was accrued in people under age 30 years in the poorest countries, while only 3% is accrued under age 30 years in high-income countries. We conclude although the current global targets for noncommunicable disease and CVD control will help diminish premature CVD death in the poorest populations, they are not sufficient. Specifically, the current framework (1) excludes deaths of people <30 years of age and deaths attributable to congenital heart anomalies, and (2) emphasizes interventions to prevent and treat conditions attributed to behavioral and metabolic risks factors. We recommend a complementary strategy for the poorest populations that targets premature death at younger ages, addresses environmental and infectious risks, and introduces broader integrated health system interventions, including cardiac surgery for congenital and rheumatic heart disease.
Collapse
Affiliation(s)
- Gene F Kwan
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.).
| | - Bongani M Mayosi
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - Ana O Mocumbi
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - J Jaime Miranda
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - Majid Ezzati
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - Yogesh Jain
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - Gisela Robles
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - Emelia J Benjamin
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - S V Subramanian
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| | - Gene Bukhman
- From Department of Medicine, Boston University School of Medicine, MA (G.F.K.); Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA (G.F.K., G.B.); Partners In Health, Boston, MA (G.F.K., G.B.); Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa (B.M.M.); Universidade Eduardo Mondlane and the Instituto Nacional de Saúde, Maputo, Mozambique (A.O.M.); Department of Medicine, School of Medicine Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (J.J.M.); MRC-PHE Centre for Environment and Health, and Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK (M.E.); Jan Swasthya Sahyog, Village and Post Ganiyari, Bilaspur (Chhattisgarh), India (Y.J.); Oxford Department of International Development, University of Oxford, UK (G.R.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA (S.V.S.); and Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA (G.B.)
| |
Collapse
|
25
|
Keenan M, Chaplin JH. A New Era for Chagas Disease Drug Discovery? PROGRESS IN MEDICINAL CHEMISTRY 2015; 54:185-230. [DOI: 10.1016/bs.pmch.2014.12.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
26
|
Abstract
American trypanosomiasis, or Chagas disease, is the result of infection by the Trypanosoma cruzi parasite. Endemic in Latin America where it is the major cause of death from cardiomyopathy, the impact of the disease is reaching global proportions through migrating populations. New drugs that are safe, efficacious, low cost, and adapted to the field are critically needed. Over the past five years, there has been increased interest in the disease and a surge in activities within various organizations. However, recent clinical trials with azoles, specifically posaconazole and the ravuconazole prodrug E1224, were disappointing, with treatment failure in Chagas patients reaching 70% to 90%, as opposed to 6% to 30% failure for benznidazole-treated patients. The lack of translation from in vitro and in vivo models to the clinic observed for the azoles raises several questions. There is a scientific requirement to review and challenge whether we are indeed using the right tools and decision-making processes to progress compounds forward for the treatment of this disease. New developments in the Chagas field, including new technologies and tools now available, will be discussed, and a redesign of the current screening strategy during the discovery process is proposed.
Collapse
Affiliation(s)
- Eric Chatelain
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| |
Collapse
|
27
|
Effects of chlorate on the sulfation process of Trypanosoma cruzi glycoconjugates. Implication of parasite sulfates in cellular invasion. Acta Trop 2014; 137:161-73. [PMID: 24879929 DOI: 10.1016/j.actatropica.2014.05.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2014] [Revised: 05/17/2014] [Accepted: 05/20/2014] [Indexed: 02/06/2023]
Abstract
Sulfation, a post-translational modification which plays a key role in various biological processes, is inhibited by competition with chlorate. In Trypanosoma cruzi, the agent of Chagas' disease, sulfated structures have been described as part of glycolipids and we have reported sulfated high-mannose type oligosaccharides in the C-T domain of the cruzipain (Cz) glycoprotein. However, sulfation pathways have not been described yet in this parasite. Herein, we studied the effect of chlorate treatment on T. cruzi with the aim to gain some knowledge about sulfation metabolism and the role of sulfated molecules in this parasite. In chlorate-treated epimastigotes, immunoblotting with anti-sulfates enriched Cz IgGs (AS-enriched IgGs) showed Cz undersulfation. Accordingly, a Cz mobility shift toward higher isoelectric points was observed in 2D-PAGE probed with anti-Cz antibodies. Ultrastructural membrane abnormalities and a significant decrease of dark lipid reservosomes were shown by electron microscopy and a significant decrease in sulfatide levels was confirmed by TLC/UV-MALDI-TOF-MS analysis. Altogether, these results suggest T. cruzi sulfation occurs via PAPS. Sulfated epitopes in trypomastigote and amastigote forms were evidenced using AS-enriched IgGs by immunoblotting. Their presence on trypomastigotes surface was demonstrated by flow cytometry and IF with Cz/dCz specific antibodies. Interestingly, the percentage of infected cardiac HL-1 cells decreased 40% when using chlorate-treated trypomastigotes, suggesting sulfates are involved in the invasion process. The same effect was observed when cells were pre-incubated with dCz, dC-T or an anti-high mannose receptor (HMR) antibody, suggesting Cz sulfates and HMR are also involved in the infection process by T. cruzi.
Collapse
|
28
|
Hotez PJ, Alvarado M, Basáñez MG, Bolliger I, Bourne R, Boussinesq M, Brooker SJ, Brown AS, Buckle G, Budke CM, Carabin H, Coffeng LE, Fèvre EM, Fürst T, Halasa YA, Jasrasaria R, Johns NE, Keiser J, King CH, Lozano R, Murdoch ME, O'Hanlon S, Pion SDS, Pullan RL, Ramaiah KD, Roberts T, Shepard DS, Smith JL, Stolk WA, Undurraga EA, Utzinger J, Wang M, Murray CJL, Naghavi M. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 2014; 8:e2865. [PMID: 25058013 PMCID: PMC4109880 DOI: 10.1371/journal.pntd.0002865] [Citation(s) in RCA: 663] [Impact Index Per Article: 66.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Affiliation(s)
- Peter J. Hotez
- National School of Tropical Medicine at Baylor College of Medicine, Houston, Texas, United States of America
- Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Houston, Texas, United States of America
- James A. Baker III Institute at Rice University, Houston, Texas, United States of America
- * E-mail: (PJH); (CJLM); (MN)
| | - Miriam Alvarado
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
| | | | - Ian Bolliger
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
| | - Rupert Bourne
- Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom
| | | | - Simon J. Brooker
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Ami Shah Brown
- Inovio Pharmaceuticals, Inc., Blue Bell, Pennsylvania, United States of America
| | - Geoffrey Buckle
- Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America
| | | | - Hélène Carabin
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
| | - Luc E. Coffeng
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
- Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Eric M. Fèvre
- Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom
- International Livestock Research Institute, Nairobi, Kenya
| | - Thomas Fürst
- Imperial College London, London, United Kingdom
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Yara A. Halasa
- Brandeis University, Waltham, Massachusetts, United States of America
| | - Rashmi Jasrasaria
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
| | - Nicole E. Johns
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
| | - Jennifer Keiser
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Charles H. King
- Case Western Reserve University, Cleveland, Ohio, United States of America
| | - Rafael Lozano
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
| | | | | | | | - Rachel L. Pullan
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | | | - Thomas Roberts
- Stanford University School of Medicine, Stanford, California, United States of America
| | - Donald S. Shepard
- Brandeis University, Waltham, Massachusetts, United States of America
| | - Jennifer L. Smith
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Wilma A. Stolk
- Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | | | - Jürg Utzinger
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Mengru Wang
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
| | - Christopher J. L. Murray
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
- * E-mail: (PJH); (CJLM); (MN)
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America
- * E-mail: (PJH); (CJLM); (MN)
| |
Collapse
|
29
|
Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, Ballering G, Bisio M, Koren G, García-Bournissen F. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 2014; 8:e2907. [PMID: 24853169 PMCID: PMC4031103 DOI: 10.1371/journal.pntd.0002907] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Accepted: 04/16/2014] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long term cardiac morbidity. Treatment of children with benznidazole is effective, but no pediatric pharmacokinetics data are available and clinical pharmacology information on the drug is scarce. PATIENTS AND METHODS Prospective population pharmacokinetic (PK) cohort study in children 2-12 years old with Chagas disease treated with oral benznidazole 5-8 mg/kg/day BID for 60 days. (clinicaltrials.gov #NCT00699387). RESULTS Forty children were enrolled in the study. Mean age was 7.3 years. A total of 117 samples were obtained from 38 patients for PK analysis. A one compartment model best fit the data. Weight-corrected clearance rate (CL/F) showed a good correlation with age, with younger patients having a significantly higher CL/F than older children and adults. Simulated median steady-state benznidazole concentrations, based on model parameters, were lower for children in our study than for adults and lowest for children under 7 years of age. Treatment was efficacious in the 37 patients who completed the treatment course, and well tolerated, with few, and mild, adverse drug reactions (ADRs). DISCUSSION Observed benznidazole plasma concentrations in children were markedly lower than those previously reported in adults (treated with comparable mg/kg doses), possibly due to a higher CL/F in smaller children. These lower blood concentrations were nevertheless associated to a high therapeutic response in our cohort. Unlike adults, children have few adverse reactions to the drug, suggesting that there may be a direct correlation between drug concentrations and incidence of ADRs. Our results suggest that studies with lower doses in adults may be warranted. TRIAL REGISTRATION ClinicalTrials.gov NCT00699387.
Collapse
Affiliation(s)
- Jaime Altcheh
- Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina
| | - Guillermo Moscatelli
- Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina
| | - Guido Mastrantonio
- Área de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Provincia de Buenos Aires, Argentina
| | - Samanta Moroni
- Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina
| | - Norberto Giglio
- Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina
| | - Maria Elena Marson
- Área de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Provincia de Buenos Aires, Argentina
| | - Griselda Ballering
- Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina
| | - Margarita Bisio
- Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina
| | - Gideon Koren
- Division of Clinical Pharmacology & Toxicology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | - Facundo García-Bournissen
- Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina
- Division of Clinical Pharmacology & Toxicology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
- * E-mail:
| |
Collapse
|
30
|
Keenan M, Chaplin JH, Alexander PW, Abbott MJ, Best WM, Khong A, Botero A, Perez C, Cornwall S, Thompson RA, White KL, Shackleford DM, Koltun M, Chiu FCK, Morizzi J, Ryan E, Campbell M, von Geldern TW, Scandale I, Chatelain E, Charman SA. Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. J Med Chem 2013; 56:10158-70. [PMID: 24304150 PMCID: PMC3884847 DOI: 10.1021/jm401610c] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
![]()
Chagas
disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health.
Available medicines were introduced over 40 years ago, have undesirable
side effects, and give equivocal results of cure in the chronic stage
of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed
curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic,
show no adverse effects in vivo following repeat dosing, are prepared
by a short synthetic route, and have druglike properties suitable
for preclinical development.
Collapse
Affiliation(s)
- Martine Keenan
- Epichem Pty Ltd. , Murdoch University Campus, South Street, Murdoch, Western Australia 6150, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ayo CM, Dalalio MMDO, Visentainer JEL, Reis PG, Sippert EÂ, Jarduli LR, Alves HV, Sell AM. Genetic susceptibility to Chagas disease: an overview about the infection and about the association between disease and the immune response genes. BIOMED RESEARCH INTERNATIONAL 2013; 2013:284729. [PMID: 24069594 PMCID: PMC3771244 DOI: 10.1155/2013/284729] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/29/2013] [Revised: 05/09/2013] [Accepted: 05/31/2013] [Indexed: 01/05/2023]
Abstract
Chagas disease, which is caused by the flagellate parasite Trypanosoma cruzi, affects 8-10 million people in Latin America. The disease is endemic and is characterised by acute and chronic phases that develop in the indeterminate, cardiac, and/or gastrointestinal forms. The immune response during human T. cruzi infection is not completely understood, despite its role in driving the development of distinct clinical manifestations of chronic infection. Polymorphisms in genes involved in the innate and specific immune response are being widely studied in order to clarify their possible role in the occurrence or severity of disease. Here we review the role of classic and nonclassic MHC, KIR, and cytokine host genetic factors on the infection by T. cruzi and the clinical course of Chagas disease.
Collapse
Affiliation(s)
- Christiane Maria Ayo
- Program of Biosciences Applied to Pharmacy, Department of Clinical Analysis and Biomedicine, Maringa State University, Avenida Colombo 5790, 87020900 Maringa, PR, Brazil
| | | | | | | | | | | | | | | |
Collapse
|
32
|
|
33
|
Keenan M, Alexander PW, Diao H, Best WM, Khong A, Kerfoot M, Thompson RCA, White KL, Shackleford DM, Ryan E, Gregg AD, Charman SA, von Geldern TW, Scandale I, Chatelain E. Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorg Med Chem 2013; 21:1756-63. [PMID: 23462713 DOI: 10.1016/j.bmc.2013.01.050] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2012] [Revised: 01/16/2013] [Accepted: 01/23/2013] [Indexed: 10/27/2022]
Abstract
A scaffold hopping exercise undertaken to expand the structural diversity of the fenarimol series of anti-Trypanosoma cruzi (T. cruzi) compounds led to preparation of simple 1-[phenyl(pyridin-3-yl)methyl]piperazinyl analogues of fenarimol which were investigated for their ability to inhibit T. cruzi in vitro in a whole organism assay. A range of compounds bearing amide, sulfonamide, carbamate/carbonate and aryl moieties exhibited low nM activities and two analogues were further studied for in vivo efficacy in a mouse model of T. cruzi infection. One compound, the citrate salt of 37, was efficacious in a mouse model of acute T. cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days.
Collapse
Affiliation(s)
- Martine Keenan
- Epichem Pty Ltd, Murdoch University Campus, South Street, Murdoch, Western Australia 6150, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Calvet CM, Melo TG, Garzoni LR, Oliveira FOR, Neto DTS, N S L M, Meirelles L, Pereira MCS. Current understanding of the Trypanosoma cruzi-cardiomyocyte interaction. Front Immunol 2012; 3:327. [PMID: 23115558 PMCID: PMC3483718 DOI: 10.3389/fimmu.2012.00327] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Accepted: 10/16/2012] [Indexed: 11/13/2022] Open
Abstract
Trypanosoma cruzi, the etiological agent of Chagas disease, exhibits multiple strategies to ensure its establishment and persistence in the host. Although this parasite has the ability to infect different organs, heart impairment is the most frequent clinical manifestation of the disease. Advances in knowledge of T. cruzi-cardiomyocyte interactions have contributed to a better understanding of the biological events involved in the pathogenesis of Chagas disease. This brief review focuses on the current understanding of molecules involved in T. cruzi-cardiomyocyte recognition, the mechanism of invasion, and on the effect of intracellular development of T. cruzi on the structural organization and molecular response of the target cell.
Collapse
Affiliation(s)
- Claudia M Calvet
- Laboratório de Ultra-estrutura Celular, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz Rio de Janeiro, Rio de Janeiro, Brazil
| | | | | | | | | | | | | | | |
Collapse
|